Indiscriminate T rans -Cleavage Activity of CRISPR/SuCas12a2 Enables Sensitive Detection of SARS-CoV-2
ACS Sensors · 24.07.2026 · 11 (7) · 5397-5403
DOI: 10.1021/acssensors.6c00990 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Sensors, online erschienen am 03.07.2026. Verfasst von Zilong Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of California, Riverside, Riverside, California92521, United States. Hauptthemen laut MEDLINE: SARS-CoV-2, CRISPR-Cas Systems, COVID-19, CRISPR-Associated Proteins. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Sensitive detection of SARS‑CoV‑2 remains critical for controlling COVID‑19 outbreaks and guiding patient care. Although reverse transcription-polymerase chain reaction (RT‑PCR), the gold standard for detecting SARS-CoV-2, is highly sensitive, the need for specialized equipment and trained personnel limits its widespread application in low or middle-resource settings. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology could overcome these limitations by providing simplicity, low cost, and high specificity. However, current CRISPR-based diagnostics can simultaneously cleave the target and fluorescence probes, as they are the same nucleic acid type (ssDNA or ssRNA), thereby reducing detection sensitivity. Herein, we developed a novel CRISPR-based viral detection method using SuCas12a2 (Cas12a2 from Sulfuricurvum sp. PC08-66), which harnesses its unique broad trans-cleavage activity and offers flexibility in selecting fluorescence probes. Using the conserved SARS‑CoV‑2 envelope gene as the model analyte, the analytical performance of the CRISPR/SuCas12a2 system for viral detection was evaluated. The CRISPR/SuCas12a2 detection workflow achieved a detection limit of 5 × 103 copies/μL for SARS-CoV-2 viral RNA. When detecting nasopharyngeal swab samples from patients, the CRISPR/SuCas12a2 system showed preliminary agreement with RT-qPCR in a set of clinical samples. Our CRISPR/SuCas12a2 system provides a flexible detection platform with simplified probe selection and enhanced compatibility, offering new insights into future portable diagnostic applications and enhancing global public health surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, University of California, Riverside, Riverside, California92521, United States.
- Department of Biological Systems Engineering, Virginia Polytechnic Institute and State University, Blacksburg, Virginia24061, United States.
- Department of Microbiology, Immunology & Tropical Medicine, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia20037, United States.
- The District of Columbia Center for AIDS Research, Washington, District of Columbia20052, United States.
ORCID-Profile: Tathagata Pal, August Pfeilsticker, Juhong Chen
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Liu, Z., He, Y., Lin, X., Pal, T., Pfeilsticker, A., Liu, B. M., & Chen, J. (2026). Indiscriminate T rans -Cleavage Activity of CRISPR/SuCas12a2 Enables Sensitive Detection of SARS-CoV-2. ACS Sensors, 11(7), 5397-5403. https://doi.org/10.1021/acssensors.6c00990
Vancouver
Liu Z, He Y, Lin X, Pal T, Pfeilsticker A, Liu BM, et al. Indiscriminate T rans -Cleavage Activity of CRISPR/SuCas12a2 Enables Sensitive Detection of SARS-CoV-2. ACS Sensors. 2026;11(7):5397-5403. doi:10.1021/acssensors.6c00990
BibTeX
@article{Liu2026,
author = {Liu, Zilong and He, Yawen and Lin, Xiaodong and Pal, Tathagata and Pfeilsticker, August and Liu, Benjamin M and Chen, Juhong},
title = {Indiscriminate T rans -Cleavage Activity of CRISPR/SuCas12a2 Enables Sensitive Detection of SARS-CoV-2},
journal = {ACS Sensors},
year = {2026},
volume = {11},
number = {7},
pages = {5397--5403},
doi = {10.1021/acssensors.6c00990}
}
EUVIMED